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ABSTRACT The aim of this prospective study was to analyze comorbidities in patients 
with palmoplantar pustulosis (PPP). The current study comprised 63 consecutive pa-
tients with palmoplantar pustulosis. The control group consisted of 37 patients with 
psoriasis vulgaris (PSV). The study included a standardized anamnesis, a clinical ex-
amination, blood tests for thyroid hormones, as well as calcium, magnesium, antien-
domysial antibody, and patch tests.
Hypertension was observed in 28/63 (44.44%) patients with PPP. Eight (12.7%) had 
ischaemic heart disease, and 7/63 (11.11%) had type 2 diabetes mellitus. There was no 
statistically significant difference between the patients with PPP and those in the con-
trol group. Metabolic syndrome was diagnosed in 19/63 (30.16%) patients with PPP 
and in 12/37 (32.43%) patients with PSV. Thyroid disease was more prevalent among 
patients with PPP in comparison to patients with PSV (31.75% vs. 13.51%; p=0.0421). 
Body mass index was statistically significantly higher in patients with PSV (28.25 vs. 
25.86 kg/m², p=0.0144). BMI was higher than 25 kg/m2 in 18.03% patients with PPP 
and 26.47% patients with PSV (p=0.333). Positive patch tests were observed in 12/39 
(30.77%) patients with PPP. The most common allergens were nickel chloride (5/12, 
41.67%) and fragrances (5/12, 41.67%). In the control group, patch tests were posi-
tive in 2/11 (18.18%) cases (p<0.05). Patients with PPP, like patients with PSV, often 
presented with hypertension and metabolic syndrome. Given that many studies have 
focused on cardiovascular risk in PSV, there is a need for further research on the as-
sociation between PPP and cardiovascular risk. In addition, patients resistant to PPP 
treatment should be screened for contact allergies.
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INTRodUCTIoN
Palmoplantar pustulosis (PPP) is an entity of un-
known nosological origin. Some authors claim that it 
belongs to the spectrum of psoriasis, whereas others 
suggest it is of a different nature and a distinct dis-
ease. Palmoplantar pustulosis is characterized by an 
eruption of pustules on an erythemato-desquama-
tive background on the palms and/or the soles. Not 
much has been reported in the literature about this 
condition. The term palmoplantar pustulosis was in-
troduced by Lever in 1967 (1). In the 1970s and 1980s, 
differences between PPP and vulgar psoriasis (PSV) 
were noticed, but greater interest was taken in PPP 
only in the 1990s. Subsequent immunological and im-
munohistochemical studies proposed the concept of 
PPP as an autoimmunological disease (in contrast to 
chronic plaque psoriasis) (1-6). Recently, Becher et al. 
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(7) published a retrospective review of comorbidities 
in patients with PPP. However, there is still a need for 
further studies on comorbidities in patients with PPP.
PATIeNTS ANd MeTHodS
The study was conducted in the Department of 
Dermatology, Medical University of Warsaw, Poland, 
between 2011 and 2014. 
A total of 63 patients with skin lesions correspond-
ing to those seen in palmoplantar pustulosis were 
enrolled in the study. The control group consisted of 
37 patients with skin lesions corresponding to those 
associated with chronic plaque psoriasis (PSV) occa-
sionally occurring on the hands or feet. The control 
group was matched to the study group by age and 
sex to compare concomitant diseases and the results 
of laboratory tests.
The characteristic skin lesions (Fig. 1) were the in-
clusion criterion. The exclusion criterion was an unspe-
cific clinical presentation. None of the patients received 
biological treatment prior to or during the study.
The study included:
1. Self-designed standardized anamnesis contain-
ing questions about the disease, concomitant diseas-
es, and treatment. 
2. Clinical examination that described skin and 
nail changes.
a. Body Mass Index (BMI = mass (kg)/ height² (m²)) 
was measured.
b. Metabolic syndrome was diagnosed according 
to specific criteria (8).
3. Laboratory tests were conducted for thyroid 
hormones, calcium, magnesium, and antiendomysial 
antibodies.
4. Data regarding the treatment regimen were ob-
tained from the medical documentation.
5. Patch testing was conducted using one of two 
sets of allergens (Table 1):
a. the first set of allergens by Polish Patch Test 
Company I (mgr farm. Edmund Jaworski, Katowice, 
Poland),
b. the second set of allergens with TRUE TEST pan-
els 1 and 2 by SmartPractice Denmark Aps
The interpretation of the patch tests was as fol-
lows: negative reaction (−); doubtful (+/−) faint ery-
thema; weak positive (+) erythema, discrete papules; 
strong positive (++) papules, discrete vesicles; and 
extreme positive (+++) coalescing vesicles/bullous 
reaction.
The study protocol was approved by the Bioethi-
cal Committee at the Medical University of Warsaw 
(KB 13/2011). All study participants provided writtne 
informed consent to the survey. 
Statistical analyses
The results were computed with Statistica 8.0 soft-
ware (StatSoft Inc.) licensed to the Medical University 
Figure 1. Clinical presentation of PPP skin lesions.
Set of allergens Polish 
Patch Test Company, mgr 
farm. Edmund Jaworski, 
Katowice, Poland
TRUE TEST panel 1and 2 by 
SmartPractice Denmark Aps
Budezonid Nickel sulphate
Fragrance cocktail A Wool alcohols
Potassium dichromate Neomycin sulphate
Nickel chloride Potassium dichromate
p-Phenylenediamine Caine mix
Formalin Fragrance mix
IPPD= Nonox ZA Colophony
Balsam of Peru Epoxy resin
Mercaptobenzothiazole Quinoline mix




Cobalt (I) chloride P-tert butylphenol formalde-
hyderesin
Fragrance cocktail P Paraben mix
Thiuram mix Carba mix









Table 1. Two sets of allergens used for patch testing
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of Warsaw. The Kolmogorov-Smirnov, Shapiro-Wilk 
test and visual analyses were used for assessing the 
normal distribution of the sample. Continuous vari-
ables were tested for statistically significant differenc-
es using the Student’s t-test and the Mann-Whitney 
test where appropriate. Spearman rank correlation 
coefficients were computed to estimate possible in-
terrelations. Fisher’s exact test was used for testing bi-
nary variables. A p-value below 0.05 was considered 
statistically significant. 
ReSULTS
The study group comprised 63 patients with 
palmoplantar pustulosis, of which 58 (92.06%) were 
women. The control group comprised 37 patients 
with PSV – 34 (89.19%) women and three men. There 
was no difference between the groups regarding age 
and sex. (Table 2).
The onset of the disease in patients with PPP was 
between 14 and 75 years of age, on average at 48.5 
[95% confidence interval (CI)13.06]. This was sta-
tistically significantly later than in the patients with 
PSV who were in the control group (38.73±20.97; 
p=0.038). In the PPP group, one peak in incidence was 
observed; this was in contrast to two peaks in the PSV 
group (Fig. 2 & 3). The mean duration of the disease 
was 10.0 ± 11.59 years. In 15 patients, skin lesions 
appeared first on the palms; in 29, on the soles; and 
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   Table 2. Baseline demographics and clinical disease characteristics.
Variable PPP n=63 
PSV
n=37 P
Female (%)  58 (92,06) 34 (89,19) 0,9444
Age mean ± Sd, years 58,51 ± 12,4 57,03 ± 14,39 0,7330
disease onset ± Sd, years 48,51 ± 13,06 38,73 ± 20,97 0,0379
Triggering factors:  No of pts (%)
stres 11 (17,46) 15(40,54) 0,0111
infections 16 (25,40) 15 (40,54) 0,1139
smoking 60 (95,23) 23 (62,16) 0,001
packyears of smoking 24,04 15,97 0,0095
Positive family history of PSV, No of pts (%) 14 (22,22) 15 (40,54) 0,0502
Finger nail involvement, No of pts (%) 28 (44,44) 22 (59,46) 0,1471
Toe nail involvement, No of pts (%) 26 (41,27) 14 (37,84) 0,7352
Systemic treatment, No of pts (%)
Acitretin 25 (39,7) 4 (10,81) 0,0021
Methotrexate 11 (17,5) 3 (8,11) 0,1932
Local- PUVA 13 (20,6) 2 (5,41) 0,0395
Re-local PUVA 2 (3,2) 0
UVB 311 2 (3,2) 10 (27,03) 0,0004
CsA 1 (1,6) 2 (5,41) 0,2799
Fumarans 1 (1,6) 0
Glucocorticosteroids 8 (12,7) 0
Figure 2. Age at the onset of the disease in PPP patients 
(years).
Figure 3. Age at the onset of the disease in PSV patients 
(years).
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N  (%) N (%)
Thyroid diseases 20 (31.75) 5 (13.51) 0.0421
diabetes mellitus type 2 7 (11.11) 7 (18.92) 0.2773
Hypertension 28 (44.44) 17 (45.95) 0.8841
Ischaemic heart disease 8 (12.7) 6 (16.21) 0.624
Metabolic syndrome 19 (30.16) 12 (32.43) 0.8124
BMI (kg/m²) 25.86 28.25 0.0144
BMI > 25 kg/m²; No of pts 11/61 (18.03) 9/34 (26.47) 0.333
CoPd 2 (3.17) 1 (2.70) 0.8937
Atopy 12 (19.05) 3 (8.11) 0.1391
Atopic dermatitis 1 (1.59) 0 (0) 0.4412
Hay fever 11 (17.46) 2 (5.41) 0.0835
Allergic conjunctivitis 8 (12.70) 1 (2.70) 0.0917
Asthma 1 (1.59) 1 (2.70) 0.7233
Psychiatric disorders 11 (17.46) 6 (16.22) 0.8730
depression 9 (14.28) 4 (10.81)
others 2 (3.18) 2 (5.4)
Arthralgia, No of pts 36 (57.14) 15 (43.24) 0.1792
The onset of arthralgia, years 51.32 48.21 0.1946
The intensity of joint pains,  0-10 5.37 1.58 0.0001
BMI—body mass index; COPD—Chronic Obstructive Pulmonary Disease
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in 11 on the palms and soles simultaneously. During 
the period of exacerbation, pustules were observed 
on the palms in 52 subjects and on the soles in 61 
subjects.
In 24/54 (44.44%) patients with PPP, the disease 
presented with a chronic course. Long remissions of 
more than 6 months were noted in 13/37 (35.14%) 
cases. In 9/13 (69.23%) cases, there was a long-lasting 
symptom-free period of at least 18 months after the 
first flare-up.
TRIGGeRING FACToRS
The most common triggering factors (Table 2) in 
the study group were stress and infections, as in PSV; 
however, existing skin lesions in PSV patients were 
more frequently exacerbated by stress (40.54% vs. 
17.46%; p=0.0111).
Forty-five (45) patients with PPP were smokers, 
and 15 had smoked in the past (a total of 60 subjects, 
95.23%). In addition, two patients were passive smok-
ers at home. On the contrary, 23/37 (62.16%) PSV pa-
tients reported smoking during the study (37.84%) 
or in the past (p=0.001). The patients with PPP had 
Table 3. Comorbidities in patients with PPP and PSV
Figure 4. The onset of the disease in PPP patients with a 
positive family history of PSV.
Figure 5. A comparison of the severity of joint pain evalu-
ated on a 0–10 scale, in PPP and PSV patients.
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Alergen N (%) Alergen N (%)
Nickel chloride 5 (41.67%) Colophony 1 (8.33%)
Potassium dichromate 1 (8.33%) Eucerin 1 (8.33%)
Cobalt chloride 2 (16,67%) Formalin 2 (16.67%)
Fragrance cocktail P 2 (16.67%) Terpentinepara 1 (8.33%)
Fragrance cocktail A 3 (25%) p-Phenylenediamine 1 (8.33%)
Balsam of Peru 2 (16.67%) Neomycin 1 (8.33%)
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smoked for a statistically significantly longer time (for 
29.7 vs. 19.3 years; p=0.0022) and had smoked for a 
higher number of pack-years (24.03 vs. 15.97; p<0.01) 
than the patients with PSV.
In the study group (PPP), the onset of the disease 
was observed before menopause in 24/58 (41.38%) 
female patients with PPP, in 7/58 (12.07%) during per-
imenopause, and in 27/58 (46.55%) after menopause. 
In addition, postmenopausal exacerbations were 
observed in 3/58 (4.76%) female patients. Meno-
pause did not influence the course of the disease in 
9 (14.29%) patients.
Two patients were pregnant. Remission of the dis-
ease was observed in one patient during pregnancy 
and up to 6 months after delivery. For the other pa-
tient, the course of the disease did not change during 
pregnancy, but an exacerbation of skin lesions was 
observed after delivery. 
In the control group (PSV), the onset of the dis-
ease was observed in 21/33 (63.64%) female subjects 
before menopause, in 3/33 (9.09%) during perimeno-
pause, and in 10/33 (30.3%) after menopause. In addi-
tion, exacerbations after menopause were observed 
in 5/33 (15.15%) patients.
ASSoCIATIoN wITH PSV
In the PPP group, patients reported a positive 
family history of PPP (3/63, 4.76%) and PSV (14/63, 
22.22%). PSV skin lesions were observed periodically 
in 17/63 (26.98%) patients with PPP. However, no oc-
currence of scalp lesions, generalized skin lesions, or 
psoriatic erythroderma was observed in any of the 
subjects with PPP. Patients with PPP and  positive 
family history of the disease presented with an ear-
lier onset in comparison to the group without a PSV 
family history (at the age of 42.5 vs. 50.22, p=0.0149) 
(Figure 4).
In the study group, fingernail involvement was 
observed in 44.44% cases, and toenail involvement 
in 41.27% cases. Among the most common changes 
were nail pitting (17.46%), followed by onycholysis 
and subungal changes (pustules, hyperkeratosis) 
(11.11% for both) – all typical for PSV. Less frequently 
occurring uncharacteristic nail changes were also re-
ported (7.95%). There was no statistically significant 
difference in fingernail changes between the group 
with PPP and the one with PSV (44.44% vs. 59.46%, 
p=0.1471), except for onycholysis – PSV vs. PPP 
(36.11% vs 11.11%; p=0.0029).
CoMoRBIdITIeS
Among 63 patients with PPP, 28 (44.44%) had hy-
pertension, 8 (12.7%) had ischaemic heart disease 
(IHD), and 7 (11.11%) had type 2 diabetes mellitus 
(Table 3).
Metabolic syndrome was diagnosed in 19/63 
(30.16%) patients with PPP and in 12/37 (32.43%) 
patients with PSV. There was no statistical difference 
(p=0.8124). 
Eleven (11/61 (18.03%)) patients with PPP and 
9/34 (26.47%) patients with PSV had a BMI greater 
than 25kg/m2 (p=0.333). Although the mean BMI was 
statistically significantly higher in patients with PSV 
(28.25 vs. 25.86 kg/m², p=0.0144), the mean body 
mass index was elevated in both groups of patients 
(PPP and PSV), indicating overweight. 
No statistically significant difference in the inci-
dence of hypertension, IHD, type 2 diabetes mellitus, 
chronic obstructive pulmonary disease, or atopy was 
observed (Table 3).
Thyroid disease was more prevalent among pa-
tients with PPP in comparison to patients with PSV 
(31.75% vs. 13.51%; p=0.0421). The most common 
were thyroiditis (Hashimoto, Graves-Basedow dis-
ease) and goiter. 
Thirty-six (36/63, 57.14%) PPP patients suffered 
from joint pain. The beginning of arthralgia started on 
Table 4. The results of patch tests in patients  with PPP
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average at the age of 51.32 [CI 95% ±14.95], (age range 
20–78). No statistical difference was found in the fre-
quency of the onset of joint pain in the two groups. 
However, it was discovered that the intensity of joint 
pain, evaluated on a 0–10 scale (Figure 5), was higher 
in patients with PPP (5.374 vs. 1.584; p=0.0001). Most 
often, pain affected the knee joints, followed by ankle 
and shoulder joints. Among the patients with arthral-
gia, seven had been diagnosed with arthritis prior to 
the study – psoriatic arthritis (4), rheumatoid arthritis 
(1), SAPHO syndrome (1), arthritis of the jaw (1), and 
one (1) during the diagnostic procedures. According 
to the rheumatological observation, the remaining 28 
patients with arthralgia were suspected of psoriatic 
arthritis, but did not fulfill the diagnostic criteria.
PATCH TeSTING
The results of the patch tests (Table 4) were posi-
tive in 12/39 (30.77%) patients with PPP. The most 
common allergens were nickel chloride (5/12, 41.67%) 
and fragrances (a total of 5/12, 41.67%).  Multivalent 
allergies were present in eight cases. In the control 
group, patch tests were positive in 2/11 (18.18%) 
cases (p<0.05). In both cases, multivalent allergies 
were present (nickel, dichromate, and p-phenylene-
diamine). 
LABoRAToRy TeSTS
None of the 24 subjects with PPP had detectable 
IgA or IgG antiendomysial autoantibodies. 
No statistical difference in the levels of calcium 
(9.11 vs. 9.05mg/dL; p=0.6603) or magnesium (2.06 
vs. 2.05 mg/dL; p=0.7041) was found in patients with 
PPP and PSV. In 48 (88.89%) patients with PPP, calci-
um levels were within the normal range. It was lower 
in 3 (5.56%) and elevated in 3 (5.56%) patients.
TReATMeNT
The treatment of PPP was based on topical agents: 
potent glucocorticosteroids, exfoliating agents (sali-
cylic acid), retinoids (tazarotene), Vitamin D3 deriva-
tives (calcipotriol), and emollients. Thirty-six (36/63, 
57.14%) subjects were treated with systemic meth-
ods. The most common systemic methods included 
acitretin (25/63, 39.7%), local-PUVA (13/63, 20.6%), 
and methotrexate (Mtx) (11/63, 17.5%). Eight patients 
(12.7%) were treated with systemic glucocorticoste-
roids by rheumatologists because of accompanying 
arthritis.
Acitretin was administered in 20-40 mg doses 
per day. The treatment lasted between 3 weeks and 
3 years, but usually 1-3 months. An improvement of 
more than 75% was noted in about 50% of the cases 
of skin lesions. A rapid recurrence of the disease (5/12) 
and short remissions of up to three months were ob-
served (4/12) in the study group. In 10/24 cases, side 
effects resulted in the discontinuation of treatment.
Medical documentation was available for only 
5/13 subjects treated with local-PUVA. An improve-
ment of more than 75% was observed in 3/5 patients 
with lesions, including one for whom a 5-month re-
mission was observed. In the remaining two subjects, 
no remission was observed. A single dose ranged 
from 0.75 to 4.0 J/cm², and the total dose ranged from 
59.5 to 104 J/cm².
Methotrexate was administered in doses of 12.5 to 
25 mg/week because of skin lesions (4/10) or arthritis 
(6/10). Rheumatologists treated three patients with-
out skin lesions with Mtx and systemic glucocortico-
steroids. In only one subject to whom Mtx was admin-
istered in a dose of 25 mg/week for 12 months one 
year of remission of skin lesions was achieved. No clin-
ical change was observed in 4/7 (57.14%) subjects. 
dISCUSSIoN
A review of the literature identified the general 
characteristics of patients with palmoplantar pustu-
losis in various populations, e.g., Swedish, Japanese, 
German, Austrian or Spanish (9-14). Despite some 
similarities among these populations, a few differ-
ences were described. The presence of anti-gliadin 
antibodies and coeliac disease, as well as an elevated 
level of calcium, was characteristic for Swedish pa-
tients with PPP (9, 15, 16). Pustulotic arthro-osteitis 
(PAO) was prevalent in Japanese patients. In one 
study, 70/469 (14.9%) of patients presented with 
PAO (10). Interestingly, a high incidence of PPP was 
not observed among Japanese females (10, 17). The 
prevalence of PPP in the Japanese population at large 
was estimated at 0.12% (95% confidence interval (CI), 
0.12% to 0.12%) (18). 
In our study of Polish patients with PPP, more than 
90% of the subjects were women, with an average 
age of 58.5 years. In addition, the results regarding 
the association between smoking and thyroid disease 
were consistent with a majority of the characteristics 
of PPP cases described in the literature (9, 11, 19).
In comparison to the studies in the Swedish popu-
lation (9, 16), our study found no antiendomysial au-
toantibodies or celiac disease in any of the 24 sub-
jects in the PPP group who presented with IgA or IgG. 
The results were consistent with the observations of 
Weisenseel et al. (20). Moreover, there was no statisti-
cal difference in the calcium or magnesium levels of 
the subjects with PPP or PSV. The results did not con-
firm the observations of Hagforsen et al. (15). 
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Concomitant diseases
Metabolic syndrome is the name for a group of 
risk factors that lead to an increased risk of cardiovas-
cular disease and type 2 diabetes. The new criteria for 
the diagnosis of metabolic syndrome were published 
in the Third Report of the National Cholesterol Edu-
cation Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol 
in Adults (8).
Many reports have been published about meta-
bolic syndrome in individuals with psoriasis. A meta-
analysis of 41,853 PSV cases revealed that a patient 
with metabolic syndrome has twice the risk for de-
veloping psoriasis in comparison to individuals in 
the general population, for developing psoriasis (21). 
In another study, Langan et al. (22) showed that the 
severity of psoriasis was positively correlated with 
metabolic syndrome. In patients with mild psoria-
sis (BSA <2%), metabolic syndrome was diagnosed 
in 32% of cases. In subjects with moderate psoriasis 
(BSA 2–10%), it was diagnosed in 36% of cases, and 
in subjects with severe psoriasis (BSA > 10%), it was 
diagnosed in 40% of cases (22).
In the current study, metabolic syndrome was 
diagnosed in the PPP group in 30.16% of the cases 
and in the control group (PSV) in 32.43% of the cases, 
with no statistically significant difference (p=0.8124). 
There was no statistically significant difference in the 
percentage of subjects with elevated BMI (>25kg/
m2) in the PPP and PSV groups, although the mean 
BMI was higher in subjects with PSV in comparison 
to those with PPP (28.25 vs. 25.86 kg/m², respectively, 
p=0.0144). In the Tratter H. et al. study the metabolic 
syndrome was observed in 26% (24, 41) of patients 
with PPP (14).
 In addition, there was no statistical difference in 
the prevalence of ischaemic heart disease, hyperten-
sion, or type 2 diabetes mellitus between the groups. 
The results were consistent with the study of Atas and 
Gonul (23). They did not find the difference between 
the fasting glucose, insulin and the homeostatic 
model assessment (HOMA index) between the PPP 
and control groups (23). 
It might be interesting to compare the prevalence 
of metabolic syndrome in patients with PPP and 
those in the general population. 
Joint pain quite often accompanied PPP. It was 
present in 57.14% of the PPP cases in the our study. 
Knee joints were affected most often. Among the 
subjects with arthralgia, arthritis was diagnosed in 
more than 20% of cases. The SAPHO syndrome was 
observed in one case. No pustulotic arthro-osteitis 
(PAO), which was a characteristic in Japanese popula-
tions (10), was observed in our study group. The litera-
ture related to joint pain in PPP mostly describes rare 
diseases like Sonozoki syndrome, SAPHO syndrome, 
or chronic recurrent multifocal osteomyelitis (24-26). 
Reports regarding the concomitance of arthralgia and 
PPP are rare. In one study, arthralgia was reported in 
25/59 (42.37%) cases, mostly in hand joints (9).
A review of the literature revealed only a few stud-
ies describing the association between PPP and con-
tact allergies. In a study of a group of 40 subjects with 
PPP, positive patch tests were observed in 6 (15%) 
cases (19). In another study, 9/15 (60%) patients with 
PPP presented with positive patch tests, with 7 cases 
exhibiting polyvalent allergies (27). Fragrances were 
the most common allergens. Interestingly, in 7/9 sub-
jects with positive patch tests, the avoidance of aller-
gens caused an improvement of skin lesions.
Case studies have suggested that flare-ups of PPP 
lesions might be associated with treatments with 
dental fillings. In one case, the development of skin 
lesions on the palms and soles started after dental 
treatment with medications, including zinc. The re-
placement of the dental fillings with those without 
zinc resulted in the remission of the lesions (28). In 
another case, PPP skin lesions resistant to treatment 
regressed following the removal of dental amalgams. 
In those cases, patch tests were positive for metal al-
lergens (29, 30).
In our study, positive patch tests were found in 
30.77% patients with PPP. Polyvalent allergies were 
noted in 8 cases. The most common allergens were 
nickel chloride and fragrances. 
These observations all indicate that patients with 
PPP might need screening for contact allergies. 
Treatment
In our study, the majority of patients were treated 
with systemic methods, including acitretin (39.7%), 
local-PUVA (20,6%), and methotrexate (17.5%). Acitre-
tin had high efficacy, although recurrences of lesions 
were observed very soon after the withdrawal of the 
drug. 
There are a few reports about the effectiveness 
of local-PUVA in PPP (31-34). However, the combined 
treatment of retinoid and PUVA (Re-PUVA) seems to 
be the most effective method (35).  
Based on single reports, Mtx could be the second- 
or third-line treatment in PPP, especially in patients 
with arthritis and contraindications to acitretin (36).
Sevrain et al. published a systematic literature 
review and recommendations for the treatment of 
PPP (37). For the first-line treatment of PPP without 
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PsA, potent or very potent topical glucocorticoste-
roids were proposed. For the second-line treatment, 
a combination therapy of acitretin and local photo-
therapy or monotherapy of one of the methods was 
suggested. For the third-line treatment, ciclosporin 
and methotrexate were recommended (37). These 
recommendations were consistent with our clinical 
observations with one exception–namely, that topi-
cal benzoyl peroxide or retinoids could be an alterna-
tive for topical glucocorticosteroids.
Other studies have documented the use of bio-
logical treatments for PPP. In one open study, Bisson-
nette et al. showed that etanercept might be effec-
tive in some patients with PPP (38). In another study, 
a randomized controlled trial with a group of 33 pa-
tients with PPP, ustekinumab did not show significant 
efficacy (39). In an observational descriptive study, a 
complete or partial response to treatment without 
adverse events was observed in only 5/11 (45%) sub-
jects with PPP (40). 
Recently, many new report about the treatment in 
PPP were published, including excimer laser, calcipot-
riol- clobetasol propionate combination (41), apremi-
last (42), ustekinumab (43) and guselkumab (44) as 
well as a systematic review on biologic therapy (45).
Nosological position of PPP
The nosological position of PPP has already been 
discussed by authors of this paper in (46). In this con-
text, the biggest question arises about the relation-
ship between PPP and PSV. What distinguishes PPP 
and PSV is undoubtedly the high incidence among 
women patients, the association with smoking and 
thyroid disease, as well as the statistically significantly 
later onset of PPP, which has already been described 
(9, 11) and confirmed in our study of Polish patients. 
Although PSV skin lesions were observed peri-
odically in 17/63 (26.98%) patients with PPP, none of 
them presented with scalp involvement, generalized 
skin lesions, or psoriatic erythroderma. This would 
have been quite unusual in 63 patients with PSV. In 
addition, onycholysis was statistically less prevalent 
in PPP patients despite the seemingly similar fre-
quency of the occurrence of nail changes in PPP and 
PSV patients (36.11% vs. 11.11%). The above observa-
tions, as well as those in genetic studies (47, 48), point 
to a distinction between PPP and PSV. 
Nevertheless, some observations lead to a hint that 
there might be a relationship between PPP and PSV. A 
positive family history of vulgar psoriasis, PSV skin le-
sions, and many types of nail changes characteristic of 
PSV were reported for the study group. In both groups 
of patients, joint pain was observed with similar fre-
quency. It is worth noting that PSV and PPP are the most 
common side effects affecting the skin from therapies 
with biologicals, especially anti-TNF-α (43-46). This im-
plies some shared etiopathological pathways.
In our study, the group of patients with PPP was 
heterogeneous. We did not find any condition that in-
fluenced the course of the disease or the response to 
treatment. Only a positive PSV family history resulted 
in the onset of the disease being eight years earlier 
than in other patients. In our opinion, we can distin-
guish at least two groups among PPP patients: one 
with a chronic course of the disease and significant 
resistance to treatment and the other with a mild 
course of the disease. 
In approximately 25-30% of subjects, PPP was 
associated with vulgar psoriasis; however, in the 
remaining 70-75% of patients, no association was 
found between PPP and PSV. In addition, the disease 
in these patients showed features that were distinct 
from those associated with PSV. 
CoNCLUSIoN
Patients with PPP, like patients with PSV, often pre-
sented with hypertension and metabolic syndrome. 
Given that many studies have focused on the cardiovas-
cular risk in PSV (53), there is a need for more research 
on the association between PPP and the risk for cardio-
vascular disease. In addition, patients resistant to PPP 
treatment should be screened for contact allergies.
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